Irene C Huffnagel1, Fiza K Laheji2, Razina Aziz-Bose2, Nicholas A Tritos3, Rose Marino4, Gabor E Linthorst5, Stephan Kemp6, Marc Engelen1, Florian Eichler2. 1. Department of Pediatric Neurology/Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands. 2. Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. 3. Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 4. Department of Pediatric Endocrinology, Massachusetts General Hospital, Boston, Massachusetts. 5. Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, Netherlands. 6. Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, Netherlands.
Abstract
Context: Primary adrenal insufficiency is an important clinical manifestation of X-linked adrenoleukodystrophy (ALD). Other manifestations include spinal cord disease and/or inflammatory demyelinating cerebral disease. Implementation of newborn screening requires natural history data to develop follow-up recommendations. Objective: To delineate the natural history of adrenal insufficiency in male patients with ALD and to assess associations between the risk for developing adrenal insufficiency, spinal cord disease, or cerebral disease and plasma C26:0/C22:0 and C24:0/C22:0 ratios, which are diagnostic biomarkers for ALD. Design: Retrospective review of medical records. Setting: Two international tertiary referral centers of expertise for ALD. Patients: Male patients with ALD followed at the centers between 2002 and 2016. Main Outcome Measures: The primary endpoint was adrenal insufficiency; secondary endpoints were spinal cord and cerebral disease. Results: Data on 159 male patients was available. The probability of developing adrenal insufficiency was described with survival analysis. Median time until adrenal insufficiency was 14 years (95% CI, 9.70 to 18.30 years). The cumulative proportion of patients who developed adrenal insufficiency was age-dependent and highest in early childhood [0 to 10 years, 46.8% (SEM 0.041%); 11 to 40 years, 28.6% (SEM, 0.037%); >40 years, 5.6% (SEM, 0.038%)]. No association between clinical manifestations and plasma ratios was detected with Cox model or Spearman correlation. Conclusions: Lifetime prevalence of adrenal insufficiency in male patients with ALD is ~80%. Adrenal insufficiency risk is time-dependent and warrants age-dependent follow-up. Besides on-demand testing if symptoms manifest, we suggest a minimum of adrenal testing every 4 to 6 months for patients age ≤10 years, annual testing for those age 11 to 40 years, and solely on-demand testing for those age >40 years.
Context: Primary adrenal insufficiency is an important clinical manifestation of X-linked adrenoleukodystrophy (ALD). Other manifestations include spinal cord disease and/or inflammatory demyelinating cerebral disease. Implementation of newborn screening requires natural history data to develop follow-up recommendations. Objective: To delineate the natural history of adrenal insufficiency in male patients with ALD and to assess associations between the risk for developing adrenal insufficiency, spinal cord disease, or cerebral disease and plasma C26:0/C22:0 and C24:0/C22:0 ratios, which are diagnostic biomarkers for ALD. Design: Retrospective review of medical records. Setting: Two international tertiary referral centers of expertise for ALD. Patients: Male patients with ALD followed at the centers between 2002 and 2016. Main Outcome Measures: The primary endpoint was adrenal insufficiency; secondary endpoints were spinal cord and cerebral disease. Results: Data on 159 male patients was available. The probability of developing adrenal insufficiency was described with survival analysis. Median time until adrenal insufficiency was 14 years (95% CI, 9.70 to 18.30 years). The cumulative proportion of patients who developed adrenal insufficiency was age-dependent and highest in early childhood [0 to 10 years, 46.8% (SEM 0.041%); 11 to 40 years, 28.6% (SEM, 0.037%); >40 years, 5.6% (SEM, 0.038%)]. No association between clinical manifestations and plasma ratios was detected with Cox model or Spearman correlation. Conclusions: Lifetime prevalence of adrenal insufficiency in male patients with ALD is ~80%. Adrenal insufficiency risk is time-dependent and warrants age-dependent follow-up. Besides on-demand testing if symptoms manifest, we suggest a minimum of adrenal testing every 4 to 6 months for patients age ≤10 years, annual testing for those age 11 to 40 years, and solely on-demand testing for those age >40 years.
Authors: Jia Zhu; Florian Eichler; Alessandra Biffi; Christine N Duncan; David A Williams; Joseph A Majzoub Journal: Endocr Rev Date: 2020-08-01 Impact factor: 19.871
Authors: E J Mallack; G Askin; S van de Stadt; P A Caruso; P L Musolino; M Engelen; S N Niogi; F S Eichler Journal: AJNR Am J Neuroradiol Date: 2021-09-09 Impact factor: 4.966
Authors: Eric James Mallack; Keith P Van Haren; Anna Torrey; Stephanie van de Stadt; Marc Engelen; Gerald V Raymond; Ali Fatemi; Florian S Eichler Journal: Neurology Date: 2022-05-24 Impact factor: 11.800
Authors: Quentin Raas; Malu-Clair van de Beek; Sonja Forss-Petter; Inge Me Dijkstra; Abigail Deschiffart; Briana C Freshner; Tamara J Stevenson; Yorrick Rj Jaspers; Liselotte Nagtzaam; Ronald Ja Wanders; Michel van Weeghel; Joo-Yeon Engelen-Lee; Marc Engelen; Florian Eichler; Johannes Berger; Joshua L Bonkowsky; Stephan Kemp Journal: J Clin Invest Date: 2021-04-15 Impact factor: 14.808
Authors: Eric J Mallack; Bela R Turk; Helena Yan; Carrie Price; Michelle Demetres; Ann B Moser; Catherine Becker; Kim Hollandsworth; Laura Adang; Adeline Vanderver; Keith Van Haren; Maura Ruzhnikov; Joanne Kurtzberg; Gustavo Maegawa; Paul J Orchard; Troy C Lund; Gerald V Raymond; Molly Regelmann; Joseph J Orsini; Elisa Seeger; Stephan Kemp; Florian Eichler; Ali Fatemi Journal: J Inherit Metab Dis Date: 2021-01-09 Impact factor: 4.982
Authors: Katie Wiens; Susan A Berry; Hyoung Choi; Amy Gaviglio; Ashish Gupta; Amy Hietala; Daniel Kenney-Jung; Troy Lund; Weston Miller; Elizabeth I Pierpont; Gerald Raymond; Holly Winslow; Heather A Zierhut; Paul J Orchard Journal: Am J Med Genet A Date: 2019-05-10 Impact factor: 2.802